Bernhard J. Eigl

10.3k total citations · 2 hit papers
135 papers, 4.6k citations indexed

About

Bernhard J. Eigl is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Bernhard J. Eigl has authored 135 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Pulmonary and Respiratory Medicine, 52 papers in Surgery and 46 papers in Oncology. Recurrent topics in Bernhard J. Eigl's work include Prostate Cancer Treatment and Research (48 papers), Bladder and Urothelial Cancer Treatments (33 papers) and Radiopharmaceutical Chemistry and Applications (25 papers). Bernhard J. Eigl is often cited by papers focused on Prostate Cancer Treatment and Research (48 papers), Bladder and Urothelial Cancer Treatments (33 papers) and Radiopharmaceutical Chemistry and Applications (25 papers). Bernhard J. Eigl collaborates with scholars based in Canada, United States and United Kingdom. Bernhard J. Eigl's co-authors include Kim N., Christian Kollmannsberger, Scott North, Martin Gleave, Peter Venner, Daniel Y.C. Heng, Arun Azad, Jennifer J. Knox, Joseph D. Ruether and Tina Cheng and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Scientific Reports.

In The Last Decade

Bernhard J. Eigl

127 papers receiving 4.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

2009 1.5k citations Bernhard J. Eigl, Scott North et al. Journal of Clinical Oncology profile →
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer

2018 347 citations Matti Annala, Gillian Vandekerkhove et al. Cancer Discovery profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Bernhard J. Eigl	3.2k	1.7k	1.6k	1.5k	820	135	4.6k
Neeraj Agarwal	3.4k 1.1×	1.9k 1.1×	1.4k 0.9×	1.6k 1.0×	1.1k 1.3×	207	4.8k
Mary J. MacKenzie	3.9k 1.2×	1.8k 1.1×	1.5k 1.0×	2.0k 1.3×	657 0.8×	67	5.3k
Roberto Iacovelli	2.6k 0.8×	1.5k 0.9×	1.2k 0.8×	2.1k 1.4×	712 0.9×	224	4.6k
D. Scott Ernst	2.8k 0.9×	1.2k 0.7×	767 0.5×	1.8k 1.1×	925 1.1×	77	4.3k
Michael Siebels	3.4k 1.1×	2.7k 1.6×	1.6k 1.0×	1.6k 1.0×	626 0.8×	65	5.2k
Lauren C. Harshman	2.8k 0.9×	1.4k 0.8×	1.2k 0.7×	1.8k 1.1×	1.2k 1.4×	194	4.3k
Giuseppe Procopio	3.1k 1.0×	1.5k 0.9×	1.2k 0.8×	2.7k 1.8×	615 0.8×	360	5.2k
Stéphane Culine	2.0k 0.6×	1.4k 0.8×	1.0k 0.7×	1.6k 1.1×	1.7k 2.1×	163	4.6k
Antoine Thiery-Vuillemin	2.4k 0.7×	1.2k 0.7×	985 0.6×	2.0k 1.3×	292 0.4×	155	3.7k
Barbara J. Gitlitz	2.8k 0.9×	2.2k 1.3×	855 0.6×	1.9k 1.2×	752 0.9×	118	4.5k

Countries citing papers authored by Bernhard J. Eigl

Since Specialization

Citations

This map shows the geographic impact of Bernhard J. Eigl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernhard J. Eigl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernhard J. Eigl more than expected).

Fields of papers citing papers by Bernhard J. Eigl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernhard J. Eigl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernhard J. Eigl. The network helps show where Bernhard J. Eigl may publish in the future.

Co-authorship network of co-authors of Bernhard J. Eigl

This figure shows the co-authorship network connecting the top 25 collaborators of Bernhard J. Eigl. A scholar is included among the top collaborators of Bernhard J. Eigl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernhard J. Eigl. Bernhard J. Eigl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nip, Ka Mun, Arman Rahmim, Robert H. Bell, et al.. (2025). Machine Learning Model Integrating Computed Tomography Image–Derived Radiomics and Circulating miRNAs to Predict Residual Teratoma in Metastatic Nonseminoma Testicular Cancer. JCO Clinical Cancer Informatics. 9(9). e2500105–e2500105. 1 indexed citations

Calvo, Emiliano, Bernard Doger, Joan Carles, et al.. (2025). A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancer. The Oncologist. 30(1). 2 indexed citations

Eigl, Bernhard J., et al.. (2025). NEO-BLAST: Neoadjuvant therapy for bladder cancer followed by active surveillance vs treatment.. Journal of Clinical Oncology. 43(5_suppl). 1 indexed citations

Black, Peter C. & Bernhard J. Eigl. (2024). The Evolving Role of PD-(L)1 Inhibition in Optimizing Outcomes for High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): A Podcast. Advances in Therapy. 41(3). 915–927. 1 indexed citations

Vandekerkhove, Gillian, Andrew J. Murtha, David C. Müller, et al.. (2024). Abstract A007: Circulating tumor DNA and tissue staining analyses reveal heterogeneous ERBB2/HER2 status in urothelial cancer. Clinical Cancer Research. 30(10_Supplement). A007–A007.

Blais, Normand, Nimira Alimohamed, Lori Wood, et al.. (2024). 2024 CUA-GUMOC Expert Report: Management of unresectable locally advanced and metastatic urothelial carcinoma. Canadian Urological Association Journal. 18(12). 379–90. 1 indexed citations

Schönlau, Elena, David C. Müller, Gillian Vandekerkhove, et al.. (2023). Evaluating the use of circulating tumor DNA (ctDNA) in patients with urothelial cancer in the context of FGFR-targeted therapy.. Journal of Clinical Oncology. 41(16_suppl). 4577–4577.

Petrylak, Daniel P., Bernhard J. Eigl, Saby George, et al.. (2023). Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma. Clinical Cancer Research. 30(1). 63–73. 2 indexed citations

Annala, Matti, Sinja Taavitsainen, Daniel Khalaf, et al.. (2021). Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition. Clinical Cancer Research. 27(16). 4610–4623. 52 indexed citations

10.

Soleimani, Maryam, Katherine Sunderland, Werner J. Struss, et al.. (2021). Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score–weighted comparative cohort study. European Journal of Cancer. 152. 215–222. 11 indexed citations

11.

Vandekerkhove, Gillian, Jean‐Michel Lavoie, Matti Annala, et al.. (2021). Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nature Communications. 12(1). 184–184. 109 indexed citations

12.

Black, Peter C., Nimira Alimohamed, David M. Berman, et al.. (2020). Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection. Canadian Urological Association Journal. 14(8). E373–E382. 6 indexed citations

13.

Annala, Matti, Gillian Vandekerkhove, Daniel Khalaf, et al.. (2018). Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. Cancer Discovery. 8(4). 444–457. 347 indexed citations breakdown →

14.

Paolucci, Iwan, Bernhard J. Eigl, Anja Lachenmayer, et al.. (2018). An augmented reality navigation system for laparoscopic liver surgery – First experiences. HPB. 20. S265–S266. 2 indexed citations

15.

Vandekerkhove, Gillian, Tilman Todenhöfer, Matti Annala, et al.. (2017). Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. Clinical Cancer Research. 23(21). 6487–6497. 122 indexed citations

16.

Bellmunt, Joaquim, Bernhard J. Eigl, Elżbieta Senkus, et al.. (2017). Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer. Annals of Oncology. 28(10). 2481–2488. 19 indexed citations

17.

Nappi, Lucia, Ladan Fazli, K.N. Chi, et al.. (2017). Biological assessment of viable germ cell tumor (VT) in patients (pts) with seminoma (S) and non-seminoma (S) using miR371. Annals of Oncology. 28. v325–v325. 1 indexed citations

18.

Bellmunt, Joaquim, Arjun Vasant Balar, Matthew D. Galsky, et al.. (2016). IMvigor210: updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma (mUC). Annals of Oncology. 27. vi270–vi270. 10 indexed citations

19.

Petrylak, Daniel P., Elisabeth I. Heath, Guru Sonpavde, et al.. (2016). Interim analysis of a phase I dose escalation trial of the antibody drug conjugate (ADC) AGS15E (ASG-15ME) in patients (Pts) with metastatic urothelial cancer (mUC). Annals of Oncology. 27. vi269–vi269. 27 indexed citations

20.

Eigl, Bernhard J., Peter Venner, Sébastien J. Hotte, et al.. (2011). A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a. Annals of Oncology. 23(1). 53–58. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact